NO20091045L - 3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler - Google Patents

3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler

Info

Publication number: NO20091045L
Authority: NO; Norway
Prior art keywords: hdl cholesterol; angioplasty; pyridinecarboxamide; increasing agents; pyrazinecarboxamide derivatives
Prior art date: 2006-10-04

Application number

NO20091045A

Other languages

English (en)

Norwegian (no)

Inventor

Paul Hebeisen

Stephan Roever

Matthias Heinrich Nettekoven

Ulrike Obst Sander

Mirjana Andjelkovic

Agnes Benardeau

Evelyne Chaput

Constantinos G Panousis

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-04

Filing date

2009-03-10

Publication date

2009-03-31

2009-03-10 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2009-03-31 Publication of NO20091045L publication Critical patent/NO20091045L/no

Links

DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title 2
239000003795 chemical substances by application Substances 0.000 title 1
229960003966 nicotinamide Drugs 0.000 title 1
235000005152 nicotinamide Nutrition 0.000 title 1
239000011570 nicotinamide Substances 0.000 title 1
IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical class NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 title 1
238000002399 angioplasty Methods 0.000 abstract 3
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
206010002383 Angina Pectoris Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
208000032928 Dyslipidaemia Diseases 0.000 abstract 1
239000004131 EU approved raising agent Substances 0.000 abstract 1
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 abstract 1
208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
206010063837 Reperfusion injury Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
206010045261 Type IIa hyperlipidaemia Diseases 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
201000001386 familial hypercholesterolemia Diseases 0.000 abstract 1
235000010855 food raising agent Nutrition 0.000 abstract 1
208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
208000028867 ischemia Diseases 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
208000031225 myocardial ischemia Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

NO20091045A 2006-10-04 2009-03-10 3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler NO20091045L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06121755		2006-10-04
PCT/EP2007/060094 WO2008040651A1 (en)	2006-10-04	2007-09-24	3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents

Publications (1)

Publication Number	Publication Date
NO20091045L true NO20091045L (no)	2009-03-31

Family

ID=38740266

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20091045A NO20091045L (no)	2006-10-04	2009-03-10	3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler

Country Status (14)

Country	Link
US (3)	US20080085906A1 (pt)
EP (2)	EP2074096B1 (pt)
JP (1)	JP2010505789A (pt)
KR (1)	KR101107896B1 (pt)
CN (1)	CN101522626A (pt)
AU (1)	AU2007304365A1 (pt)
BR (1)	BRPI0717845A2 (pt)
CA (1)	CA2664119A1 (pt)
IL (1)	IL197577A0 (pt)
MX (1)	MX2009003222A (pt)
NO (1)	NO20091045L (pt)
RU (1)	RU2454405C2 (pt)
WO (1)	WO2008040651A1 (pt)
ZA (1)	ZA200902353B (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0519058A2 (pt)	2004-12-14	2008-12-23	Astrazeneca Ab	composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
WO2007071966A1 (en)	2005-12-22	2007-06-28	Astrazeneca Ab	Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors
MX2008015228A (es)	2006-05-30	2008-12-12	Astrazeneca Ab	Acido 5-fenilamino-1,3,4-oxadiazol-2-ilcarbonilamino-4-fenoxi-cicl ohexanocarboxilico sustituido como inhibidor de diacilglicerol aciltransferasa de acetil coenzima a.
CN101460470B (zh)	2006-05-30	2011-05-18	阿斯利康(瑞典)有限公司	作为dgat1抑制剂的1,3,4-二唑衍生物
US7781593B2 (en) *	2006-09-14	2010-08-24	Hoffmann-La Roche Inc.	5-phenyl-nicotinamide derivatives
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
NZ586104A (en)	2007-12-20	2012-02-24	Astrazeneca Ab	Carbamoyl compounds as dgat1 inhibitors 190
US7897621B2 (en)	2008-03-31	2011-03-01	Hoffmann-La Roche Inc.	2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents
US8088920B2 (en) *	2008-03-31	2012-01-03	Hoffmann-La Roche Inc.	3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
CA2743134A1 (en)	2008-11-10	2010-05-14	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
ES2921576T3 (es)	2008-12-19	2022-08-29	Vertex Pharma	Compuestos útiles como inhibidores de la quinasa ATR
US8338441B2 (en) *	2009-05-15	2012-12-25	Gilead Sciences, Inc.	Inhibitors of human immunodeficiency virus replication
TW201103895A (en)	2009-06-19	2011-02-01	Astrazeneca Ab	Chemical compounds
UA107088C2 (xx) *	2009-09-11	2014-11-25		5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину
US8962631B2 (en)	2010-05-12	2015-02-24	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
EP2568984A1 (en)	2010-05-12	2013-03-20	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
US9062008B2 (en)	2010-05-12	2015-06-23	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
US9334244B2 (en)	2010-05-12	2016-05-10	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
CA2798760A1 (en)	2010-05-12	2011-11-17	Vertex Pharmaceuticals Incorporated	2-aminopyridine derivatives useful as inhibitors of atr kinase
NZ603477A (en)	2010-05-12	2014-09-26	Vertex Pharma	Compounds useful as inhibitors of atr kinase
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
MX2013000103A (es)	2010-06-23	2013-06-13	Vertex Pharma	Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
WO2012031817A1 (en)	2010-09-09	2012-03-15	F. Hoffmann-La Roche Ag	Determination of abca1 protein levels in cells
US8410107B2 (en) *	2010-10-15	2013-04-02	Hoffmann-La Roche Inc.	N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) *	2010-10-22	2012-04-26	Pascal Dott	Process for the preparation of nicotinamide derivatives
US8669254B2 (en)	2010-12-15	2014-03-11	Hoffman-La Roche Inc.	Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
MX2013011450A (es)	2011-04-05	2014-02-03	Vertex Pharma	Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
US8822469B2 (en)	2011-06-22	2014-09-02	Vertex Pharmaceuticals Incorporated	Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
US9309250B2 (en)	2011-06-22	2016-04-12	Vertex Pharmaceuticals Incorporated	Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
EP2723747A1 (en)	2011-06-22	2014-04-30	Vertex Pharmaceuticals Inc.	Compounds useful as inhibitors of atr kinase
KR20140061518A (ko) *	2011-09-12	2014-05-21	에프. 호프만-라 로슈 아게	N-(5-사이클로알킬- 또는 5-헤테로사이클릴-)-피리딘-3-일 카복스아마이드
WO2013037703A1 (en)	2011-09-12	2013-03-21	F. Hoffmann-La Roche Ag	3 -pyridine carboxylic acid hydrazides as hdl-cholesterol raising agents
WO2013037721A1 (en) *	2011-09-12	2013-03-21	F. Hoffmann-La Roche Ag	5-cycloalkyl- or 5-heterocyclyl-nicotinamides
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013049722A1 (en)	2011-09-30	2013-04-04	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
CN106496173A (zh)	2011-09-30	2017-03-15	沃泰克斯药物股份有限公司	用于制备可用作atr激酶抑制剂的化合物的方法
US8765751B2 (en)	2011-09-30	2014-07-01	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
CN108685922A (zh)	2011-09-30	2018-10-23	沃泰克斯药物股份有限公司	用atr抑制剂治疗胰腺癌和非小细胞肺癌
WO2013049720A1 (en)	2011-09-30	2013-04-04	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
US9403808B2 (en) *	2011-10-28	2016-08-02	Hoffmann-La Roche Inc.	Pyrazine derivatives
JP2015502925A (ja)	2011-11-09	2015-01-29	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
US8846918B2 (en)	2011-11-09	2014-09-30	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
US8841450B2 (en)	2011-11-09	2014-09-23	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
US8841337B2 (en)	2011-11-09	2014-09-23	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
US8846917B2 (en)	2011-11-09	2014-09-30	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
CN108478577A (zh)	2012-04-05	2018-09-04	沃泰克斯药物股份有限公司	可用作atr激酶抑制剂的化合物及其组合疗法
RU2015107550A (ru) *	2012-08-23	2016-10-10	Ф. Хоффманн-Ля Рош Аг	Новые фенилпиридин/пиразинамиды для лечения рака
DK2904406T3 (en)	2012-10-04	2018-06-18	Vertex Pharma	METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
EP2909202A1 (en)	2012-10-16	2015-08-26	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
SI2941432T1 (en)	2012-12-07	2018-07-31	Vertex Pharmaceuticals Incorporated	2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
JP6282721B2 (ja) *	2013-03-14	2018-02-21	ダート・ニューロサイエンス・（ケイマン）・リミテッド	Ｐｄｅ４阻害剤としての置換ピリジン及びピラジン化合物
WO2014143240A1 (en)	2013-03-15	2014-09-18	Vertex Pharmaceuticals Incorporated	Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
PT3077397T (pt)	2013-12-06	2020-01-22	Vertex Pharma	Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
MX373102B (es)	2014-06-05	2020-04-17	Vertex Pharma	Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
SG11201610500WA (en)	2014-06-17	2017-01-27	Vertex Pharma	Method for treating cancer using a combination of chk1 and atr inhibitors
BR112017013465A2 (pt) *	2014-12-24	2018-03-06	Lg Chem, Ltd	derivado de biarila, e, composição farmacêutica.
SG11201801856XA (en)	2015-09-18	2018-04-27	Kaken Pharmaceutical Co Ltd	Biaryl derivative and medicine containing same
AU2016331955B2 (en)	2015-09-30	2022-07-21	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
JP2021501210A (ja)	2017-10-30	2021-01-14	モントリオールハートインスティテュート	血漿コレステロールの上昇を処置する方法
PL237374B1 (pl) *	2017-11-10	2021-04-06	Lambdafin Spolka Z Ograniczona Odpowiedzialnoscia	Kompozycja farmaceutyczna zawierająca mieszaninę estru etylowego kwasu eikozapentaenowego i estru etylowego kwasu dokozaheksaenowego oraz jej zastosowanie
WO2024003259A1 (en) *	2022-06-30	2024-01-04	Bayer Aktiengesellschaft	Tead inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0104332D0 (sv) *	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
SE0104330D0 (sv) *	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
CA2527033A1 (en) *	2003-06-18	2004-12-23	Astrazeneca Ab	2-substitued 5,6-diaryl-pyrazine derivatives as cb1 modulators
RU2404164C2 (ru)	2005-04-06	2010-11-20	Ф.Хоффманн-Ля Рош Аг	Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
WO2007011760A2 (en) *	2005-07-15	2007-01-25	Kalypsys, Inc.	Inhibitors of mitotic kinesin
US7629346B2 (en) *	2006-06-19	2009-12-08	Hoffmann-La Roche Inc.	Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) *	2006-09-14	2010-08-24	Hoffmann-La Roche Inc.	5-phenyl-nicotinamide derivatives
CN101522644B (zh) *	2006-10-04	2013-04-24	霍夫曼-拉罗奇有限公司	作为cb2受体调节剂的吡嗪-2-羧酰胺衍生物
US8088920B2 (en) *	2008-03-31	2012-01-03	Hoffmann-La Roche Inc.	3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents

2007
- 2007-09-24 KR KR1020097009023A patent/KR101107896B1/ko not_active Expired - Fee Related
- 2007-09-24 JP JP2009530843A patent/JP2010505789A/ja active Pending
- 2007-09-24 AU AU2007304365A patent/AU2007304365A1/en not_active Abandoned
- 2007-09-24 EP EP07820501A patent/EP2074096B1/en not_active Not-in-force
- 2007-09-24 CN CNA2007800369086A patent/CN101522626A/zh active Pending
- 2007-09-24 MX MX2009003222A patent/MX2009003222A/es active IP Right Grant
- 2007-09-24 WO PCT/EP2007/060094 patent/WO2008040651A1/en not_active Ceased
- 2007-09-24 EP EP12153000A patent/EP2450350A1/en not_active Withdrawn
- 2007-09-24 BR BRPI0717845-0A patent/BRPI0717845A2/pt not_active IP Right Cessation
- 2007-09-24 RU RU2009116670/04A patent/RU2454405C2/ru not_active IP Right Cessation
- 2007-09-24 CA CA002664119A patent/CA2664119A1/en not_active Abandoned
- 2007-09-27 US US11/904,425 patent/US20080085906A1/en not_active Abandoned
2009
- 2009-02-06 US US12/366,692 patent/US7812028B2/en not_active Expired - Fee Related
- 2009-03-10 NO NO20091045A patent/NO20091045L/no not_active Application Discontinuation
- 2009-03-12 IL IL197577A patent/IL197577A0/en unknown
- 2009-04-03 ZA ZA200902353A patent/ZA200902353B/xx unknown
2010
- 2010-06-29 US US12/825,374 patent/US8188093B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
BRPI0717845A2 (pt)	2015-06-16
RU2454405C2 (ru)	2012-06-27
US20100267745A1 (en)	2010-10-21
WO2008040651A1 (en)	2008-04-10
KR20090075852A (ko)	2009-07-09
US8188093B2 (en)	2012-05-29
CN101522626A (zh)	2009-09-02
US20090143409A1 (en)	2009-06-04
EP2450350A1 (en)	2012-05-09
CA2664119A1 (en)	2008-04-10
EP2074096A1 (en)	2009-07-01
US7812028B2 (en)	2010-10-12
KR101107896B1 (ko)	2012-01-25
EP2074096B1 (en)	2012-06-27
AU2007304365A1 (en)	2008-04-10
US20080085906A1 (en)	2008-04-10
JP2010505789A (ja)	2010-02-25
IL197577A0 (en)	2009-12-24
RU2009116670A (ru)	2010-11-10
ZA200902353B (en)	2010-04-28
MX2009003222A (es)	2009-04-06

Legal Events

Date	Code	Title	Description
2014-04-28	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20091045L (no)	2009-03-31	3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler
PH12013502156A1 (en)	2014-01-06	1,3-oxazines as bace1 and/or bace2 inhibitors
IN2012DN00766A (pt)	2015-06-26
MX2013014007A (es)	2014-03-12	[1,3] oxazinas.
EA201391786A1 (ru)	2014-04-30	Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
WO2012104263A3 (en)	2012-09-27	1,4 oxazines as bace1 and/or bace2 inhibitors
MX2013007558A (es)	2013-08-21	1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
IN2012DN03043A (pt)	2015-07-31
MX2013010795A (es)	2013-12-06	1,3 oxazinas como inhibidores de beta-secretasa 1 (bace 1) y/o la beta-secretasa 2 (beta 2).
MX2013008213A (es)	2013-08-09	N-[3-(5-amino-3,3a,7,7a-tetrahidro-1h-2,4-dioxa-6-aza-inden-7-il) -fenil]-amidas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
PH12013502262A1 (en)	2016-01-22	Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors
MX2013014194A (es)	2014-03-21	1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
EP2571876A4 (en)	2013-12-25	SUBSTITUTED SEVEN-HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES
PH12013501480A1 (en)	2022-10-26	Novel heterocyclic derivatives and their use in the treatment of neurological disorders
EA201000365A1 (ru)	2010-10-29	Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза
WO2009111700A3 (en)	2010-03-04	Oxadiazoanthracene compounds for the treatment of diabetes
NO20081729L (no)	2008-05-16	Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
WO2007097931A3 (en)	2007-11-22	Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EA201270215A1 (ru)	2012-11-30	Apaf-1 ингибиторные соединения
WO2008127682A3 (en)	2009-05-07	Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
PH12014501334A1 (en)	2014-09-15	Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
PH12015500471A1 (en)	2015-04-20	Therapeutic agent for dyslipidemia
MX2014003408A (es)	2014-04-10	N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
NZ702254A (en)	2016-08-26	5-amino[1,4]thiazines as bace 1 inhibitors
MX2014014937A (es)	2015-03-09	Difluoro-hexahidro-ciclopentaoxazinilos y difluoro-hexahidro-benzo oxazinilos como inhibidores de beta-secretasa 1 (bace1).